OBJECTIVES:  To estimate the budget impact of Secukinumab in the management of ankylosing spondylitis in Greece. METHODS:  A budget impact model was developed to compare the cost of managing ankylosing spondylitis under two scenarios (treatment mix with and without Secukinumab) and was adapted to reflect the local treatment algorithm and resource use. Population data retrieved from OECD population statistics and were projected with the mean annual growth rate of the time series 2000-2012. Epidemiology data (prevalence and incidence) were taken from Greek literature. Market shares were based on current patient numbers by treatment regimen retrieved from University of Peloponnese data for the period June 2014-June 2015. Data on resource use were obtained from international literature and were validated by Greek clinical experts. Unit costs were taken from officially published Greek sources (Ministry of Health, Social Insurance Funds -SIFs). Only direct costs were considered in the analysis. The time horizon of the analysis was five years and the perspective adopted was that of the Social Insurance Fund (EOPYY). RESULTS:  The introduction of Secukinumab in the Greek market is expected to bring gradually increasing cost savings for the Social Insurance Fund. In particular, the total cost savings with Secukinumab, compared to the scenario without it, are expected to be €28,847 in 2016, rising up to €1.2 million by 2020. These cost savings reflect a 5% reduction in the total health care budget. Drug acquisition and administration costs account for 98.5% of total costs (weighted average of the 5-year time horizon), while other disease related costs (hospitalization and physician visits) account only for 1.3% of total management costs. CONCLUSIONS:  Inclusion of Secukinumab in the treatment mix for ankylosing spondylitis in Greece is associated with cost savings for the Greek Social Insurance Fund, ranging from €28.847 for 2016 up to €1.2 million in 2020.